Prof Heinz Ludwig speaks to ecancer about the AGMT_MM-1 phase II trial presented at the virtual EHA 2020 meeting.
He explains that this trial aims to evaluate the association between the oral microbiome and patient characteristics and treatment outcomes in patients with relapsed/refractory multiple myeloma (RRMM), who were treated with ITd (ixazomib, thalidomide, dexamethasone).
But also if the composition of the microbiome differs patients with multiple myeloma (MM) and the general population.
Prof Ludwig outlines the design of the trial ad highlights the main differences found in each patient group.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.